TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective, Multi Centre, International Registry of Male and Female Patients Newly Diagnosed With Atrial Fibrillation.
Brief Summary: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF Registry) is a non-interventional, observational study that characterized a global population of non-valvular atrial fibrillation patients. The registry was used to document global baseline characteristics, current treatment strategies and outcome measures. Characterisation of a number of AF sub-populations was also completed. GARFIELD-AF is an independent academic research initiative sponsored by the Thrombosis Research Institute (London, UK) and supported by an unrestricted research grant from Bayer AG (Berlin, Germany).


Options:
A: Arm Label: Interrupted apixaban; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interrupted apixaban | Arm Label: Uninterrupted apixaban; Type: EXPERIMENTAL; Interventions: Drug: Uninterrupted apixaban | Intervention Type: DRUG; Name: Interrupted apixaban; Assigned to Arm(s): Interrupted apixaban | Intervention Type: DRUG; Name: Uninterrupted apixaban; Assigned to Arm(s): Uninterrupted apixaban
B: Arm Label: Cohort 1; Type: N/A; Interventions: N/A | Arm Label: Cohort 2; Type: N/A; Interventions: N/A | Arm Label: Cohort 3; Type: N/A; Interventions: N/A | Arm Label: Cohort 4; Type: N/A; Interventions: N/A | Arm Label: Cohort 5; Type: N/A; Interventions: N/A
C: Arm Label: Standard medical therapy group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Catheter ablation group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Catheter ablation | Intervention Type: PROCEDURE; Name: Catheter ablation; Assigned to Arm(s): Catheter ablation group
D: Arm Label: Continuous heparin infusion group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Continuous heparin infusion | Arm Label: Intermittent heparin infusion group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intermittent heparin infusion | Intervention Type: DRUG; Name: Continuous heparin infusion; Assigned to Arm(s): Continuous heparin infusion group | Intervention Type: DRUG; Name: Intermittent heparin infusion; Assigned to Arm(s): Intermittent heparin infusion group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Intubation With Storz Videolaryngoscope® Versus Airtraq® - in an Infant Population
Brief Summary: The purpose of the pilot study is to compare new laryngoscopes for infants by assessing the equipment best suited to assist the intubation, with the best overview, shortest time to intubation and use these numbers to make a sample size calculation for the full protocol. The investigators hypothesis is that the Storz videolaryngoscope® has a better success rate than infants (\<2 years). The patients will be optimally anaesthetized with neuromuscular blockade for the intubation. All patient will be evaluated with af Macintosh blade laryngoscope, with an Airtraq® or a Storz videolaryngoscope®, and finally intubated with the other one of the later, which the patient was randomized to.


Options:
A: Arm Label: Classic laryngoscope; Type: OTHER; Interventions: Device: Miller laryngoscope | Arm Label: Videolaryngoscope; Type: OTHER; Interventions: Device: Storz videolaryngoscope | Intervention Type: DEVICE; Name: Miller laryngoscope; Assigned to Arm(s): Classic laryngoscope | Intervention Type: DEVICE; Name: Storz videolaryngoscope; Assigned to Arm(s): Videolaryngoscope
B: Arm Label: Direct Laryngoscopy; Type: ACTIVE_COMPARATOR; Interventions: Device: Miller Direct Laryngoscopy | Arm Label: KingVision Video Laryngoscope; Type: EXPERIMENTAL; Interventions: Device: Ambu KingVision Video Laryngoscope aBlade | Intervention Type: DEVICE; Name: Ambu KingVision Video Laryngoscope aBlade; Assigned to Arm(s): KingVision Video Laryngoscope | Intervention Type: DEVICE; Name: Miller Direct Laryngoscopy; Assigned to Arm(s): Direct Laryngoscopy
C: Arm Label: Storz videolaryngoscope; Type: EXPERIMENTAL; Interventions: Device: Storz videolaryngoscope | Arm Label: Airtraq; Type: ACTIVE_COMPARATOR; Interventions: Device: Airtraq | Intervention Type: DEVICE; Name: Storz videolaryngoscope; Assigned to Arm(s): Storz videolaryngoscope | Intervention Type: DEVICE; Name: Airtraq; Assigned to Arm(s): Airtraq
D: Arm Label: Video Laryngoscopy for endotracheal (ET) Placement; Type: ACTIVE_COMPARATOR; Interventions: Device: Video Laryngoscopy for ET placement, Device: Direct Laryngoscopy for ET Placement | Arm Label: Direct Laryngoscopy for ET Placement; Type: ACTIVE_COMPARATOR; Interventions: Device: Video Laryngoscopy for ET placement, Device: Direct Laryngoscopy for ET Placement | Intervention Type: DEVICE; Name: Video Laryngoscopy for ET placement; Assigned to Arm(s): Direct Laryngoscopy for ET Placement, Video Laryngoscopy for endotracheal (ET) Placement | Intervention Type: DEVICE; Name: Direct Laryngoscopy for ET Placement; Assigned to Arm(s): Direct Laryngoscopy for ET Placement, Video Laryngoscopy for endotracheal (ET) Placement

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicentre Australian Phase 2 Study to Evaluate Safety and Efficacy of Mesenchymal Stromal Cells for Treating Biologic Refractory Crohn's Disease
Brief Summary: Despite the advent of newer biologic therapies such as infliximab for Crohn's disease, a form of autoimmune inflammatory bowel disease, a proportion of patients are refractory to such therapy and require surgery. The hypothesis is that mesenchymal stromal cell therapy using third party human cultured cells will be safe and effective


Options:
A: Arm Label: Hematopoietic Stem Cell Transplant Regimen 2; Type: EXPERIMENTAL; Interventions: Biological: Hematopoietic stem cell transplantation | Intervention Type: BIOLOGICAL; Name: Hematopoietic stem cell transplantation; Assigned to Arm(s): Hematopoietic Stem Cell Transplant Regimen 2
B: Arm Label: Mesenchymal stromal cells; Type: EXPERIMENTAL; Interventions: Drug: Mesenchymal stromal cells (MSC) for infusion | Intervention Type: DRUG; Name: Mesenchymal stromal cells (MSC) for infusion; Assigned to Arm(s): Mesenchymal stromal cells
C: Arm Label: Treatment; Type: OTHER; Interventions: Procedure: Injection with freshly collected autologous adipose tissue | Intervention Type: PROCEDURE; Name: Injection with freshly collected autologous adipose tissue; Assigned to Arm(s): Treatment
D: Arm Label: Mesenchymal Stem Cells; Type: EXPERIMENTAL; Interventions: Drug: Mesenchymal Stem Cells | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Mesenchymal Stem Cells; Assigned to Arm(s): Mesenchymal Stem Cells | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Intraperitoneal Local Anaesthetic Techniques During Laparoscopic Cholecystectomy: A Double Blind Randomized Controlled Trial
Brief Summary: Pain following laparoscopic cholecystectomy (LC) results in morbidity and is a barrier to same day discharge. In several trials local anaesthetic (LA) washed over the liver and gall bladder decreases pain. In many patients pain has a strong component attributable to diaphragmatic origin. A wash of LA over the liver and gall bladder is unlikely to provide high levels of analgesia to pain fibres from the diaphragm. The investigators hypothesise that LA injected to the right hemidiaphragm during LC would be more effective than wash.

Methods Double blind randomised controlled trial of 128 consecutive subjects undergoing elective LC. Control -sham injection of diaphragm and sham wash over liver/GB with saline; Test treatment 'subperitoneal LA' - bupivocaine injection/sham wash; Internal control 'topical LA' - sham injection/bupivocaine wash. Primary outcome: pain scores in theatre recovery and the ward. Secondary outcomes: analgesic use, physiological observations, time to eating and mobilising, day case surgery.


Options:
A: Arm Label: Saline sham injection; Type: SHAM_COMPARATOR; Interventions: Other: Normal saline | Arm Label: Bupivacaine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupivacaine | Intervention Type: DRUG; Name: Bupivacaine; Assigned to Arm(s): Bupivacaine | Intervention Type: OTHER; Name: Normal saline; Assigned to Arm(s): Saline sham injection
B: Arm Label: Control; Type: SHAM_COMPARATOR; Interventions: Drug: 0.9% normal saline solution | Arm Label: Subperitoneal injection; Type: EXPERIMENTAL; Interventions: Drug: Bupivocaine | Arm Label: Topical LA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupivocaine | Intervention Type: DRUG; Name: Bupivocaine; Assigned to Arm(s): Subperitoneal injection, Topical LA | Intervention Type: DRUG; Name: 0.9% normal saline solution; Assigned to Arm(s): Control
C: Arm Label: normal saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Levobupivacaine | Arm Label: Levobupivacaine; Type: EXPERIMENTAL; Interventions: Drug: Levobupivacaine | Intervention Type: DRUG; Name: Levobupivacaine; Assigned to Arm(s): Levobupivacaine, normal saline
D: Arm Label: Intravenous lidocaine injection group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intravenous lidocaine injection | Arm Label: Intraperitoneal lidocaine irrigation group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intraperitoneal lidocaine irrigation group | Arm Label: Intravenous normal saline group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Intravenous normal saline injection | Intervention Type: DRUG; Name: Intravenous lidocaine injection; Assigned to Arm(s): Intravenous lidocaine injection group | Intervention Type: DRUG; Name: Intraperitoneal lidocaine irrigation group; Assigned to Arm(s): Intraperitoneal lidocaine irrigation group | Intervention Type: DRUG; Name: Intravenous normal saline injection; Assigned to Arm(s): Intravenous normal saline group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Trial to Assess the (Cost) Effectiveness of the Use of the Distress Thermometer by a Nurse in Addition to Usual Care for Patients Treated With Curative Intent for Breast Cancer.
Brief Summary: The use of interventions for cancer-related distress is important to reduce this distress. Distress has a negative impact on quality of life, the recovery during and after treatment and may even adversely affect survival. There is insufficient attention to the systematic approach to psychosocial problems in cancer patients in the Netherlands. A task force discussed and studied which instrument measures psychosocial problems best. The distress thermometer ("lastmeter") had the best results. A guideline is written to use the distress thermometer for patients with cancer and will be used in hospitals in the Netherlands. However, it is not clear what the effects are of the use of the distress thermometer on the psychosocial wellbeing of the patient. Furthermore, it is also unknown whether the use of the distress thermometer leads to cost-effective care. The study focuses on the use of the distress thermometer in breast cancer patients. An efficiency study (RCT) will be conducted to evaluate the systematic use of the distress thermometer and its discussion by a nurse as compared to the usual care provided to outpatients who are treated with curative intent for breast cancer by their treating physicians. The clinical and economic impact of the use of the Distress thermometer will be assessed in comparison with usual care.The recruitment of patients will take place in the out-patient clinic of a university hospital. Patients will be followed from diagnose until two years after finishing their treatment.


Options:
A: Intervention Type: BEHAVIORAL; Name: Community Interlink Program; Assigned to Arm(s): N/A
B: Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: Mini-AFTERc | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Mini-AFTERc; Assigned to Arm(s): Intervention group
C: Arm Label: intervention group; Type: ACTIVE_COMPARATOR; Interventions: Device: distress thermometer | Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: distress thermometer; Assigned to Arm(s): intervention group
D: Arm Label: Survivorship Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Survivorship Intervention | Arm Label: Facing Forward; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Facing Forward | Intervention Type: BEHAVIORAL; Name: Survivorship Intervention; Assigned to Arm(s): Survivorship Intervention | Intervention Type: BEHAVIORAL; Name: Facing Forward; Assigned to Arm(s): Facing Forward

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Trial to Assess the (Cost) Effectiveness of the Use of the Distress Thermometer by a Nurse in Addition to Usual Care for Patients Treated With Curative Intent for Breast Cancer.
Brief Summary: The use of interventions for cancer-related distress is important to reduce this distress. Distress has a negative impact on quality of life, the recovery during and after treatment and may even adversely affect survival. There is insufficient attention to the systematic approach to psychosocial problems in cancer patients in the Netherlands. A task force discussed and studied which instrument measures psychosocial problems best. The distress thermometer ("lastmeter") had the best results. A guideline is written to use the distress thermometer for patients with cancer and will be used in hospitals in the Netherlands. However, it is not clear what the effects are of the use of the distress thermometer on the psychosocial wellbeing of the patient. Furthermore, it is also unknown whether the use of the distress thermometer leads to cost-effective care. The study focuses on the use of the distress thermometer in breast cancer patients. An efficiency study (RCT) will be conducted to evaluate the systematic use of the distress thermometer and its discussion by a nurse as compared to the usual care provided to outpatients who are treated with curative intent for breast cancer by their treating physicians. The clinical and economic impact of the use of the Distress thermometer will be assessed in comparison with usual care.The recruitment of patients will take place in the out-patient clinic of a university hospital. Patients will be followed from diagnose until two years after finishing their treatment.


Options:
A: Arm Label: intervention group; Type: ACTIVE_COMPARATOR; Interventions: Device: distress thermometer | Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: distress thermometer; Assigned to Arm(s): intervention group
B: Arm Label: 1A; Type: N/A; Interventions: N/A | Arm Label: 1B; Type: N/A; Interventions: N/A | Arm Label: IIA; Type: N/A; Interventions: N/A | Arm Label: IIB; Type: N/A; Interventions: N/A
C: Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: SCP care; Type: EXPERIMENTAL; Interventions: Other: SCP care | Intervention Type: OTHER; Name: SCP care; Assigned to Arm(s): SCP care
D: Arm Label: minimal surveillance; Type: OTHER; Interventions: Other: surveillance program after completion of primary treatment | Arm Label: intensive surveillance; Type: OTHER; Interventions: Other: surveillance program after completion of primary treatment | Intervention Type: OTHER; Name: surveillance program after completion of primary treatment; Assigned to Arm(s): intensive surveillance, minimal surveillance

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Safe and Effective Vitamin D Supplementation in HIV
Brief Summary: Optimal vitamin D (vit D) concentration and metabolism are essential for normal immune function, growth, muscle, bone, and inflammatory status in children, adolescents and adults with HIV/AIDS. The impact of vit D supplementation will be evaluated for safety and efficacy using clinically important outcomes, and this will overcome the critical barrier for use of vit D supplementation in research and clinical care. Inexpensive and easy to administer, vit D supplementation may prove to be an effective and feasible treatment for symptoms and prevention of side effects for people of all ages living with HIV/AIDS in the US and around the world.


Options:
A: Arm Label: Arm A: EFV/FTC/TDF plus vitamin D3 and calcium carbonate; Type: EXPERIMENTAL; Interventions: Drug: EFV/FTC/TDF, Drug: Calcium Carbonate, Drug: Vitamin D3 | Arm Label: Arm B: EFV/FTC/TDF plus vitamin D placebo and calcium placebo; Type: EXPERIMENTAL; Interventions: Drug: EFV/FTC/TDF, Drug: Placebo for calcium carbonate, Drug: Placebo for vitamin D3 | Intervention Type: DRUG; Name: EFV/FTC/TDF; Assigned to Arm(s): Arm A: EFV/FTC/TDF plus vitamin D3 and calcium carbonate, Arm B: EFV/FTC/TDF plus vitamin D placebo and calcium placebo | Intervention Type: DRUG; Name: Calcium Carbonate; Assigned to Arm(s): Arm A: EFV/FTC/TDF plus vitamin D3 and calcium carbonate | Intervention Type: DRUG; Name: Vitamin D3; Assigned to Arm(s): Arm A: EFV/FTC/TDF plus vitamin D3 and calcium carbonate | Intervention Type: DRUG; Name: Placebo for calcium carbonate; Assigned to Arm(s): Arm B: EFV/FTC/TDF plus vitamin D placebo and calcium placebo | Intervention Type: DRUG; Name: Placebo for vitamin D3; Assigned to Arm(s): Arm B: EFV/FTC/TDF plus vitamin D placebo and calcium placebo
B: Arm Label: 4000IU; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cholecalciferol (Vit D3) | Arm Label: 7000IU; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cholecalciferol (Vit D3) | Intervention Type: DRUG; Name: Cholecalciferol (Vit D3); Assigned to Arm(s): 4000IU, 7000IU
C: Arm Label: Active Drug (extended release niacin); Type: EXPERIMENTAL; Interventions: Drug: extended release niacin | Arm Label: Observation; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: extended release niacin; Assigned to Arm(s): Active Drug (extended release niacin)
D: Arm Label: Zinc gluconate; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: zinc | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: zinc | Intervention Type: DIETARY_SUPPLEMENT; Name: zinc; Assigned to Arm(s): Placebo, Zinc gluconate

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Cell Phone Intervention in Young Adults
Brief Summary: Weight gain accelerates during early adulthood, and leads to the health consequences of obesity (high blood pressure, diabetes, heart disease, etc). Most weight loss studies enroll middle-aged adults. This study tests the hypothesis that a weight loss intervention that builds on prior research evidence but is enhanced with technological innovations will lead to weight loss in a diverse group of overweight and obese adults aged 18-35 years. The technology intervention, using cell phone applications, will be compared to an "advice only" control group and to a group receiving a more traditional personal coaching intervention.


Options:
A: Arm Label: Cell phone intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral weight loss intervention | Arm Label: Personal counseling intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral weight loss intervention | Arm Label: Advice only; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Behavioral weight loss intervention; Assigned to Arm(s): Cell phone intervention, Personal counseling intervention
B: Arm Label: Keyto intervention arm; Type: EXPERIMENTAL; Interventions: Device: Keyto device + app | Arm Label: Weight Watchers comparator arm; Type: ACTIVE_COMPARATOR; Interventions: Other: Weight Watchers app | Intervention Type: DEVICE; Name: Keyto device + app; Assigned to Arm(s): Keyto intervention arm | Intervention Type: OTHER; Name: Weight Watchers app; Assigned to Arm(s): Weight Watchers comparator arm
C: Arm Label: RIDE; Type: EXPERIMENTAL; Interventions: Behavioral: RIDE e-health application | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: RIDE e-health application; Assigned to Arm(s): RIDE
D: Arm Label: Control Group (CG); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Control Group (CG) | Arm Label: Moderate physical activity group (MPA); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Moderate physical activity group (MPA) | Arm Label: Intense physical activity group (IPA); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Intense physical activity group (IPA) | Intervention Type: BEHAVIORAL; Name: Control Group (CG); Assigned to Arm(s): Control Group (CG) | Intervention Type: BEHAVIORAL; Name: Moderate physical activity group (MPA); Assigned to Arm(s): Moderate physical activity group (MPA) | Intervention Type: BEHAVIORAL; Name: Intense physical activity group (IPA); Assigned to Arm(s): Intense physical activity group (IPA)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Intergroup Multicentre, Randomized, Controlled 3 Arm Parallel Group Study to Determine the Efficacy and Safety of Lenalidomide in Combination With Dexamethasone (RD) Versus Melphalan, Prednisone and Lenalidomide (MPR) Versus Cyclophosphamide, Prednisone and Lenalidomide (CPR) in Newly Diagnosed Elderly Multiple Myeloma Subjects
Brief Summary: This is a multicenter, randomized, controlled, 3 arm parallel group study designed to evaluate the efficacy and safety of three all-oral combinations: lenalidomide with dexamethasone (Rd) in comparison with lenalidomide in association with MP (MPR) and lenalidomide in association with cyclophosphamide - prednisone (CPR) in newly diagnosed symptomatic MM patients. This protocol also provides a substudy designed to observe asymptomatic patients excluded to the protocol that in any case could be inserted in the study.


Options:
A: Arm Label: A (Thalidomide & Dexamethasone); Type: EXPERIMENTAL; Interventions: Drug: A (Thalidomide + Dexamethasone) | Arm Label: B (Dexamethasone and placebo); Type: PLACEBO_COMPARATOR; Interventions: Drug: B (Placebo + Dexamethasone) | Intervention Type: DRUG; Name: A (Thalidomide + Dexamethasone); Assigned to Arm(s): A (Thalidomide & Dexamethasone) | Intervention Type: DRUG; Name: B (Placebo + Dexamethasone); Assigned to Arm(s): B (Dexamethasone and placebo)
B: Arm Label: Treatment Arm A (VMP Alone); Type: ACTIVE_COMPARATOR; Interventions: Drug: Velcade, Drug: Melphalan, Drug: Prednisone | Arm Label: Treatment Arm B (D-VMP); Type: EXPERIMENTAL; Interventions: Drug: Velcade, Drug: Melphalan, Drug: Prednisone, Drug: Daratumumab IV, Drug: Dexamethasone, Drug: Daratumumab SC | Intervention Type: DRUG; Name: Velcade; Assigned to Arm(s): Treatment Arm A (VMP Alone), Treatment Arm B (D-VMP) | Intervention Type: DRUG; Name: Melphalan; Assigned to Arm(s): Treatment Arm A (VMP Alone), Treatment Arm B (D-VMP) | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): Treatment Arm A (VMP Alone), Treatment Arm B (D-VMP) | Intervention Type: DRUG; Name: Daratumumab IV; Assigned to Arm(s): Treatment Arm B (D-VMP) | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): Treatment Arm B (D-VMP) | Intervention Type: DRUG; Name: Daratumumab SC; Assigned to Arm(s): Treatment Arm B (D-VMP)
C: Arm Label: Rd; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lenalidomide, dexamethasone | Arm Label: MPR; Type: EXPERIMENTAL; Interventions: Drug: Melphalan, Prednisone, Lenalidomide | Arm Label: CPR; Type: EXPERIMENTAL; Interventions: Drug: Cyclophosphamide, Prednisone, Lenalidomide | Intervention Type: DRUG; Name: Melphalan, Prednisone, Lenalidomide; Assigned to Arm(s): MPR | Intervention Type: DRUG; Name: Cyclophosphamide, Prednisone, Lenalidomide; Assigned to Arm(s): CPR | Intervention Type: DRUG; Name: Lenalidomide, dexamethasone; Assigned to Arm(s): Rd
D: Intervention Type: DRUG; Name: Thalidomide; Assigned to Arm(s): N/A

Answer: C